Kymera Therapeutics price target raised to $73 from $64 at Jefferies

Jefferies raised the firm’s price target on Kymera Therapeutics (KYMR) to $73 from $64 and keeps a Buy rating on the shares, calling out KT-621 atopic dermatitis data in December as a “key upcoming catalyst.” The firm thinks the stock’s momentum could continue if KT-621 further shows “oral Dupixent” potential, the analyst tells investors.